Niti Aayog identifies R&D investment gaps as a barrier to high-value pharma growth.
Indian firms invest roughly 7% of net sales in R&D, compared to 15-20% by global peers.
Report highlights heavy reliance on Chinese imports for APIs despite local production initiatives.
Policy recommendations include better IP predictability and strengthening industry-academia research links.